CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have completely changed the approach pertaining to tumor diagnostics and treatment. Similarly, immunotherapy has also provided much needed data about mutation, expression and prognosis, affording an unprecedented opportunity for discovering candidate drug targets and screening for immunotherapy-relevant biomarkers. Although existing web tools enable biologists to analyze the expression, mutation and prognostic data of tumors, they are currently unable to facilitate data mining and mechanism analyses specifically related to immunotherapy. Thus, we effectively developed our own web-based tool, called Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP), in which we are able to successfully screen various prognostic markers and analyze the mechanisms involved in biomarker expression and function, as well as immunotherapy. The analyses include information relevant to survival analysis, expression analysis, mutational landscape analysis, immune infiltration analysis, immunogenicity analysis and pathway enrichment analysis. This comprehensive analysis of biomarkers for immunotherapy can be carried out by a click of CAMOIP, and the software should greatly encourage the further development of immunotherapy. CAMOIP provides invaluable evidence that bridges the information between the data of cancer genomics based on immunotherapy, providing comprehensive information to users and assisting in making the value of current ICI-treated data available to all users. CAMOIP is available at https://www.camoip.net.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis
Tang, Z., Kang, B., Li, C., Chen, T., & Zhang, Z. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz430 · Cited by 5,083
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Visualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481
Cited by
Liu, C.-J., Hu, F.-F., Xie, G.-Y., Miao, Y.-R., Li, X.-W., Zeng, Y., & Guo, A.-Y. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac558 · Cited by 588
TIMER3: an enhanced resource for tumor immune analysis
Cui, H., Zhao, G., Lu, Y., Zuo, S., Duan, D., Luo, X., Zhao, H., Li, J., Zeng, Z., Chen, Q., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf388 · Cited by 144
“Resources such as CAMOIP, CancerImmu-nityQTL, GSCA, GEPIA, TIGER, and TIMEDB each offer unique strengths in areas including immune infiltration analysis, genetic variation, and immunotherapy [ 14–19 ].”
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 108
Self-citationWu, L., Sun, S., Qu, F., Sun, M., Liu, X., Sun, Q., Cheng, L., Zheng, Y., & Su, G. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03343-w · Cited by 49
Xie, W., Cheng, J. R., Hong, Z., Cai, W., Zhuo, H., Hou, J., Lin, L., Wei, X., Wang, K., Chen, X., et al. (2022) · Cancers · doi:10.3390/cancers15010164 · Cited by 55
“We also used CAMOIP [21] (http:/camoip.”
Wang, X., Liu, X., Xiao, R., Fang, Y., Zhou, F., Gu, M., Luo, X., Jiang, D., Tang, Y., You, L., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217117 · Cited by 61
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment
Lin, A., Ye, P., Li, Z., Jiang, A., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2025) · Research · doi:10.34133/research.0723 · Cited by 75
Self-citationLiu, D., Liu, Y., Zhu, W., Lu, Y., Zhu, J., Ma, X., Xing, Y., Yuan, M., Ning, B., Wang, Y., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02842-6 · Cited by 47
Immunotherapy and Cancer: The Multi-Omics Perspective
Donisi, C., Pretta, A., Pusceddu, V., Ziranu, P., Lai, E., Puzzoni, M., Mariani, S., Massa, E., Madeddu, C., & Scartozzi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063563 · Cited by 46
“Lin et al. [34] have developed a tool called CAMOIP, standing for Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer, that helps to screen various prognostic markers essential to distinguish immune responders from non-responders, identify potential beneficiaries, and monitor…”
BackgroundMethodZhu, Y., Banerjee, A., Xie, P., Ivanov, A. A., Uddin, A., Jiao, Q., Chi, J. J., Zeng, L., Lee, J. Y., Xue, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176390 · Cited by 40
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Self-citationHuang, Y., Wu, L., Sun, Y., Li, J., Mao, N., Yang, Y. A., Zhao, M., & Ren, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18215 · Cited by 23
Liu, X.-D., Zhang, Y.-T. Y., McGrail, D. J., Zhang, X., Lam, T., Hoang, A. G., Hasanov, E., Manyam, G. C., Peterson, C. B., Zhu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1003 · Cited by 23
Chen, X., Liu, Y., Tao, B.-Y., Xue, X., Zhang, X., Wang, L., Zhong, H., Zhang, J., Yang, S., & Jiang, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975847 · Cited by 25
Self-citationSLC17A9-PTHLH-EMT axis promotes proliferation and invasion of clear renal cell carcinoma
Li, W., Xu, N., Meng, X., Yuan, H., Yu, T., Miao, Q., Yang, H., Hai, B., Xiao, W., & Zhang, X. (2022) · iScience · doi:10.1016/j.isci.2022.105764 · Cited by 19
Ochman, B., Mielcarska, S., Kula, A., Dawidowicz, M., Robotycka, J., Piecuch, J., Szrot, M., Dzięgielewska-Gęsiak, S., Muc‐Wierzgoń, M., Waniczek, D., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040182 · Cited by 20
Gao, Q., Yang, L., Ye, S., Mai, M., Liu, Y., Jiang, X., Feng, X., & Yang, Z. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv0766 · Cited by 26
Xu, L., Liu, Y.-H., Zhang, H.-Q., Wu, L., Li, Q., Deng, J., Zhang, Q., Yang, Y., Zhang, C., Li, Y.-L., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03047-w · Cited by 22
Huang, L., Li, H., Zhang, C., Chen, Q., Liu, Z., Zhang, J., Luo, P., & Wei, T. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1620 · Cited by 20
Self-citationGemcitabine-Resistant Biomarkers in Bladder Cancer are Associated with Tumor-Immune Microenvironment
Song, Y., Du, Y., Qin, C., Liang, H., Yang, W., Lin, J., Ding, M., Han, J., & Xu, T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.809620 · Cited by 22
Lin, A., Gu, T., Hu, X., Zhang, J., & Luo, P. (2022) · Journal of Immunology Research · doi:10.1155/2022/8179799 · Cited by 19
“Di ff er-ences in immunogenicity can occur due to di ff erences in TMB, DDR, NAL, or MANTIS score [32, 33], and changes in immunogenicity can be determined by comparing changes in these indexes.”
Self-citationCheng, Q., Wang, W., Liu, J., Lv, Z., Ji, W., Yu, J., Zhang, W., & Yang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173848 · Cited by 18
Self-citationZeng, L., Zhu, Y., Cui, X., Chi, J. J., Uddin, A., Zhou, Z., Song, X., Dai, M., Cristofanilli, M., Kalinsky, K. M., et al. (2024) · Advanced Science · doi:10.1002/advs.202400757 · Cited by 20
Wang, Y., Ju, X., Hua, R., Chen, J., Dai, X., Liu, L., Wang, G., Bai, Y., Hu, H., & Li, X. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02856-8 · Cited by 18
“In addition, single sample gene set enrichment analysis (ssGSEA) was performed to evaluate the immune-related signatures of each NSCLC patient [30].”
PanCanSurvPlot: A large-scale pan-cancer survival analysis web application
Lin, A., Yang, H., Shi, Y., Li, K., Chen, L., Wong, H. Z. H., Zhang, L., & Luo, P. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100062 · Cited by 20
Self-citationLiu, M., Fang, X., Wang, H., Ji, R., Guo, Q., Chen, Z., Ren, Q., Wang, Y., & Zhou, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1038932 · Cited by 16
Ma, F., Ren, M., Li, Z., Tang, Y., Sun, X., Wang, Y., Cao, N., Zhu, X., Xu, Y., Wang, R., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107499 · Cited by 14
Tong, Q., Li, D., Yin, Y., Cheng, L., & Ouyang, S. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s401430 · Cited by 14
“…immune cells present in the tumor microenvironment of each patient using three published immune infiltration algorithms (quanTIseq, 30 MCPcounter 31 and EPIC 32,33 Additionally, the gene list of the immune checkpoint molecules and immune inflammatory molecules are taken from published literature.”
MethodWu, W., Chen, L., Jia, G., Tang, Q., Han, B., Xia, S., Jiang, Q., & Liu, H. (2023) · Cancer Medicine · doi:10.1002/cam4.6172 · Cited by 13
Zhang, M., Yu, L., Sun, Y., Hao, L., Bai, J., Yuan, X., Wu, R., Hong, M., Liu, P., Duan, X., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415603 · Cited by 15
Ayub, H., Khan, M.-A., Naqvi, S. S. A., Faseeh, M., Kim, J., Mehmood, A., & Kim, Y. (2024) · Bioengineering · doi:10.3390/bioengineering11060533 · Cited by 15
“Lin et al. [47] investigated genotypic and phenotype information integration with multi-omics data.”
BackgroundIMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers
Liu, Y., Zhang, Y., Xie, W., Zhao, J., Dong, Y., Xu, C., Wang, Y., Li, M., Wang, G., Xin, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1354 · Cited by 11
“Here, PBRM1, bTMB and ATM are used as examples to illustrate these functions: (1) mutation types.”
MethodSelf-citationZhuo, S., Tang, C., Yang, L., Chen, Z., Chen, T., Wang, K., & Yang, K. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2264325 · Cited by 11
Liu, S., Wang, Z., Hu, L., Ye, C., Zhang, X., Zhu, Z., Li, J., & Shen, Q. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101982 · Cited by 13
“CAMOIP [21] database (https://www.camoip.net/) is used to explore the relevance between LINC00862 expression and immune cell levels in pan-cancer.”
Dang, Q., Liu, Z., Liu, Y., Wang, W., Yuan, W., Sun, Z., Liu, L., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953405 · Cited by 11
Self-citationThe overexpression and clinical significance of TBX15 in human gliomas
Yan, D., Yu, Y., Ni, Q., Meng, Q., Wu, H., Ding, S., Liu, X., Tang, C., Liu, Q., & Yang, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-36410-y · Cited by 10
Li, W., Meng, X., Yu, T., Shi, X., Dong, W., Ruan, H., Wang, T., & Xiao, W. Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.52 · Cited by 11
Differential roles of highly expressed PFKFB4 in colon adenocarcinoma patients
Gu, X., Dai, X., Huang, Y., Zhang, Y., Dong, L., Gao, C., & Wang, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-43619-4 · Cited by 13
Zhang, S., Zhang, X., Huang, W., Jiang, G., Mo, Y., Wei, L., Fan, P., Chen, M., & Jiang, W. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.100188 · Cited by 11
Li, C., Zhang, L., Xu, Y., Chai, D., Nan, S., Qiu, Z., Wang, W., & Deng, W. (2022) · Journal of Oncology · doi:10.1155/2022/7854297 · Cited by 10
“Finally, the “Immune Scores” template [17] from the CAMOIP website [18] was further used to analyze differences in immune infiltration and immune subtypes in LIHC patients with high and low P3H1 (median value is the cut-off).”
MethodIdentification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer
Miao, S., Ju, G., Jiang, C., Xue, B., Zhao, L., Zhang, R., Diao, H., Yu, X., Zhang, L., Pan, X., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1167676 · Cited by 10
A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
Kang, H., Zhu, X., Cui, Y., Xiong, Z., Zong, W., Bào, Y., & Jia, P. (2023) · Cancers · doi:10.3390/cancers15164094 · Cited by 14
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development
Wang, Q., Xie, B., Sun, J., Li, Z., Xiao, D., Tao, Y., & She, X. (2024) · Journal of Cancer · doi:10.7150/jca.92101 · Cited by 11
Zhan, Z., Huang, Z.-M., Zeng, R.-Q., Luo, Y., Xie, Z., Chen, Y.-Z., Chen, P., Luo, T., Sun, B., & Cheng, Z. J. (2024) · Journal of Cancer · doi:10.7150/jca.92238 · Cited by 10
Chen, D., Zhu, Q., Li, T., Fan, X., Lou, Y., Zhang, Y., Huang, K., & Sun, H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1106952 · Cited by 9
Meng, J., Yang, Y., Lv, J., Lv, H., Zhao, X., Zhang, L., Shi, W., Yang, Z., Mei, X., Chen, X., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001546 · Cited by 9
MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients
Wu, L.-Q., Wang, X.-C., He, X., Li, Q., Hua, Q., Liu, R.-R., & Qiu, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868203 · Cited by 8
Wang, G., Miao, C., Mo, L., Kahlert, U. D., Wu, J., Ou, M., Huang, R., Feng, R., Pang, W., & Shi, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1048503 · Cited by 13
Gao, M., Zhang, W., Li, X., Li, S., Wang, W., & Han, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041453 · Cited by 11
Zhang, M., Jiang, L., Liu, X.-Y., Liu, F., Zhang, H., Zhang, Y.-J., Tang, X.-M., Ma, Y., Wu, H.-Y., Diao, X., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24287 · Cited by 8
Self-citationLi, X., Li, X., Qin, J., Lei, L., Guo, H., Zheng, X., & Zeng, X. (2024) · BioFactors · doi:10.1002/biof.2129 · Cited by 10
Mou, W., Zhu, L., Yang, T., Lin, A.-Q., Lyu, Q., Guo, L.-L., Liu, Z.-B., Cheng, Q., Zhang, J., & Luo, P. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02651-6 · Cited by 7
Self-citationWang, W., Hua, S., Li, J., Zhao, J., Zhang, Y., Jiang, J., & Han, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1081091 · Cited by 7
“net/) (41), groups with different expression level of MOXD1 were analysed in Rose cohort and Mariathasan cohort (42, 43).”
MethodGui, J., Yang, L., Liu, J., Li, Y., Zou, M., Sun, C., Huang, L., Zhu, X., & Huang, K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24236 · Cited by 8
Yan, X., Li, Z., Jiang, A., Chen, J., Huang, X., Hajdú, A., Wong, H. Z. H., Cheng, Q., Zhang, J., Lin, A., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002607 · Cited by 8
Self-citationLin, A., Fang, X., Zhang, P., Zhang, N., Liu, Z., Cheng, Q., Zhang, J., Tang, B., & Luo, P. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.09.007 · Cited by 13
“8 , 14–20 The circadian rhythm is a fundamental endogenous time-regulating system within organisms, which exerts temporal control over crucial physiological processes such as sleep-wake cycles, immune system function, metabolic activities, and endocrine networks through an intricate network of…”
Self-citationPrognostic significance of carboxypeptidase Q and its methylation in glioblastoma
Liu, Q., Wang, R., Li, Z., Peng, Y., Qin, W., Peng, X.-M., & Liu, Z. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2562 · Cited by 6
Self-citationLi, H., Wu, J., Xu, Q., Pang, Y., Gu, Y., Wang, M., & Cheng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05236-1 · Cited by 6
“…(GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and Gene Set Enrichment Analysis (GSEA) concerning on GEN1 were conducted using the web-based tool Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP) database (http:// www. camoip. net/) [16].”
MethodDetermination of the Immunomodulatory Role of OTOP2 in Colon Adenocarcinoma
Lu, C., Chen, S., Liu, S., Liu, H., Sun, L., & Sun, Y. (2024) · Journal of Cancer · doi:10.7150/jca.95622 · Cited by 6
RelB is a potential molecular biomarker for immunotherapy in human pan-cancer
Wu, J., Yu, X., Zhu, H., Chen, P., Liu, T., Yin, R. H., Qiang, Y., & Xu, L. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1178446 · Cited by 7
“net) was a good tool for analyzing the expression data and mutation data from TCGA and the ICI-treated projects (Lin et al., 2022).”
MethodZhu, J., Chen, Q., Zeng, L., Gao, H., Wu, T., He, Y., Xu, J., Pang, J., Peng, J., Deng, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1236806 · Cited by 5
Li, C., Liang, Z., Vontz, G., Kent, C., Ma, W., Liu, L., Dahal, R., Zabaleta, J., Cai, G., Zhou, J., et al. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101677 · Cited by 5
“Correlations of CISD1 expression and somatic mutations were obtained from the Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP) 28 by selecting the “Mutational Landscape” section.”
Zhan, Z., Huang, Z.-M., Lan, Q.-W., Luo, Y., Li, J., Zheng, Y.-F., Chen, Y.-Z., Chen, P., Luo, T., Sun, B., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12466-5 · Cited by 5
“The immunotherapy response predictive analysis of MYO9A was conducted using the CAMOIP (http:// www.camoip.net/) online tool [28].”
MethodExploring the oncogenic roles of LINC00857 in pan-cancer
Ren, X., Liu, J., Wang, R., Liu, X., Ma, X., Lü, Z., Hu, Z., Zheng, M., Ma, J., & Li, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.996686 · Cited by 6
Zhang, W., Cao, W., Tong, Z., Jin, Q., Jiang, X., Yang, Y., Yao, H., Chen, G., Gao, W., Zhu, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011000 · Cited by 5
Liu, Q., Liu, Y., Chen, X., Tao, B.-Y., Chen, K., Li, W., Xu, C.-T., Shi, Y. K., Li, H., & Liu, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1071722 · Cited by 5
Lin, Y., Liao, X., Zhang, Y., Wu, G., Ye, J., Luo, S., He, X., Luo, M., Xie, M., Zhang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920939 · Cited by 7
Self-citationUSP32 Promotes Colorectal Carcinoma Progression Through Activating NF ‐ κB Signalling Pathway
Duan, X., Yeerkenbieke, G., Huang, S., & Feng, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70457 · Cited by 4
Peng, S., Jia, K., Peng, M., Chen, Y., Lin, A., Luo, P., Wang, J., Wang, Y., & Bai, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002526 · Cited by 6
Self-citationYuan, J., Beibei, X., Su, Y., Zhang, P., Zhang, X., & Gong, P. (2025) · BMC Cancer · doi:10.1186/s12885-025-14096-x · Cited by 5
OralExplorer: a web server for exploring the mechanisms of oral inflammatory diseases
Lin, W., Yang, H. Y., Lin, J., Yang, X., Liao, Z., Zheng, Y., Luo, P., & Liu, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05019-8 · Cited by 5
“Additionally, we compared OralExplorer with many popular web-based tools, such as HPV-TIMER [38] and CAMOIP [39].”
MethodSelf-citationWFDC2 is a potential prognostic and immunotherapy biomarker in lung adenocarcinoma
Min, B., & Wang, Y. (2024) · Journal of International Medical Research · doi:10.1177/03000605241258893 · Cited by 5
From bench to bedside: elucidating VEGF(R) inhibitor-related heart failure in cancer treatment
Peng, S., Cai, M., Kuang, H., Lin, A., Ma, Q., Dai, X., Luo, P., Liu, Y., Zhang, G., & Bai, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06133-x · Cited by 4
“Utilizing pathway annotations from Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome databases within MSigDB [20– 23], we systematically assessed the activation states of diverse signaling pathways.”
Self-citationYang, Y., Yuan, L., Liu, W., Lu, D., Meng, F., Yang, Y., Zhou, Z., Ma, P., & Nan, Y. (2024) · Medicine · doi:10.1097/md.0000000000036303 · Cited by 4
“[37] In order to analyze the correlation between the core targets and the key pathways and the biological processes (BP).”
Jiang, H.-C., Gao, Y., Wang, S.-Y., Zhao, Y.-L., & Sun, H.-P. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42794 · Cited by 3
Xu, Q., Altrock, E., Schmitt, N., Streuer, A., Rapp, F., Nowak, V., Obländer, J., Weimer, N., Palme, I., Göl, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021725 · Cited by 5
“net (accessed on 14 June 2022)) [17], which allows for performing a mutational landscape analysis based on gene expression levels.”
BackgroundMethodInfluentialCACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma
Huang, Y., Lin, A., Gu, T., Hou, S., Yao, J., Luo, P., & Zhang, J. (2023) · Immunotherapy · doi:10.2217/imt-2022-0175 · Cited by 5
Self-citationLiu, Z., Yang, L., Xie, Z., Yu, H., GU, T., Shi, D., Cai, N., & Zhuo, S. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.045769 · Cited by 4
Self-citationLiang, W., Jie, H., Xie, H., Zhou, Y., Li, W., Huang, L., Liang, Z., Liu, H., Zheng, X., Zeng, Z., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1495 · Cited by 3
“Based on the online website 25 (https://www.camoip.net), lymphocyte infiltration signature score and Th1 cells in different groups of keratin expression in CRC were shown (Supplementary figure 2).”
ELF4 was a prognostic biomarker and related to immune infiltrates in glioma
Zhuang, Z., Zhang, C., Tan, Y., Zhang, J., & Zhong, C. (2024) · Journal of Cancer · doi:10.7150/jca.96886 · Cited by 3
Self-citationClinical Significance and Potential Function of Complement Factor D in Acute Myeloid Leukemia
Zhang, T., Li, Z., He, A., Zhou, W., Zhu, X., & Song, Y. (2024) · Cureus · doi:10.7759/cureus.67260 · Cited by 3
“The analysis was based on the online database Comprehensive Analysis on Multi-Omics of Immunotherapy in Pan-cancer (CAMOIP) (http://220.189.241.246:13838/) [20].”
MethodInfluentialWen, G.-M., Zhao, Z.-Y., Zheng, X.-H., Liu, D.-H., & Xia, P. (2025) · Oncology Letters · doi:10.3892/ol.2025.15191 · Cited by 3
Liu, K.-S., Chang, Y., Wu, H., & Lin, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-02723-9 · Cited by 2
“1186/ s12859- 023-05615-3) [11] and CAMOIP (https:// acade mic. oup. com/ bib/ artic le/ 23/3/ bbac1 29/ 65656 19) [12].”
Li, J. W., Deng, Z., Yan, Z., Huang, S., Jin, J., Xie, C., & Gan, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-13196-9 · Cited by 2
Integrative analysis identifies TEAD4 as a universal prognostic biomarker in human cancers
Liu, M., Song, Y., Kang, Y., Xue, N., Zhao, J., Jin, Y., Liu, C., & Wang, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688563 · Cited by 2
An, Z., Zhang, X., Li, L., Wusiman, D., Wang, Z., Zhang, F., Zhao, X., An, C., Yin, Z., & Gao, W. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025209 · Cited by 2
Fan, S.-T., Xu, H.-Q., He, Y., Tu, M.-X., Shi, K., Zhang, Y., Guo, Q., Yang, W., & Qin, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294144 · Cited by 2
Luo, P., Liu, Y., Xu, L., Liu, Z., Wang, L., Wong, H. Z. H., Cheng, Q., Lin, A., Fang, X., & Jiang, A. (2025) · View · doi:10.1002/viw.20240113 · Cited by 2
Self-citationKimura, S., Katsuya, H., Nakashima, C., Sueoka‐Aragane, N., Hayashida, K., Sasaki, K., Sogawa, R., Furuno, T., Yamauchi, M., Noshirο, H., et al. (2025) · BMC Immunology · doi:10.1186/s12865-025-00711-w · Cited by 3
“Predictive biomarkers for irAEs, such as cytokine profiles and T-cell activation markers, have been explored to optimize ICI therapy [46, 47].”
Yang, L., Ren, S., Li, L., He, J., Huang, Q., Wu, X., & Zhao, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-99038-0 · Cited by 2
Lu, C., Li, M., Yang, H., Liu, Z., Zhang, J., Cheng, Q., Lin, A., Wang, S., & Luo, P. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70025 · Cited by 2
Self-citationBhola, N., Bareja, C., Jaiswal, A. K., & Saluja, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188867 · Cited by 3
CBLN2 overexpression inhibits colorectal cancer progression and improves immunotherapy responses
Wang, Z., Pan, H., Zhou, J., & Wan, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113566 · Cited by 2
Chen, J., Yi, Y., Yang, C., Ying, H., Zhang, J., Lin, A., Wei, T., & Luo, P. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.07.043 · Cited by 4
“Recent research trends have focused on developing high-precision predictive models by integrating preclinical and clinical data[72,73].”
Self-citationRathore, V., & Lin, W. (2025) · Medicina · doi:10.3390/medicina61111894 · Cited by 1
Digestive System Toxicities of Immune Checkpoint Inhibitors: Mechanisms and Clinical Implications
Lin, A., Huang, Q., Zhang, J., & Luo, P. (2026) · BIO Integration · doi:10.15212/bioi-2025-0169 · Cited by 1
Self-citationChen, Y., Chang, Y.-H., Wu, H., & Lin, H. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00021 · Cited by 1
Li, F., Dong, K., Zhang, C., Wang, J., Tang, Y., Xue, K., Zheng, X., Song, K., Zhang, X., Li, M., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03414-6 · Cited by 2
Self-citationWill EGFRvIII and neuronal-derived EGFR be targets for imipramine?
Li, Z.-S., Wang, B., Wu, J., & Han, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1156492 · Cited by 3
Hou, S., Gu, T., Shi, Y., Huang, Y., Yao, J., Luo, P., Cao, M., Zhang, J., Lin, A., & Zhu, W. (2023) · Cancer Biomarkers · doi:10.3233/cbm-230226 · Cited by 1
“The Mann-Whitney U test was used to assess the relationships between IL3 pathway-related genes activation and TMB, immune gene [40] expression, and immune cell infiltration.”
Self-citation
Metadata
- Authors
- Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., & Zhang, J.
- Affiliations
- Zhujiang Hospital (CN)
- Central South University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Corresponding author
- Luo, Peng
- Zhang, Jian
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-04-09
- Volume
- 23
- Issue
- 3
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W4225957066
- Semantic Scholar
- 112f9aa2b6cb6450112c3508adb1124e22c2697d
- Cited by
- 152
- References
- 51
- Citations by year
- 2026: 13 · 2025: 34 · 2024: 37 · 2023: 42 · 2022: 26
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Briefings in Bioinformatics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- Natural Science Foundation of Guangdong Province (2018A030313846, 2021A1515012593)
- Science and Technology Planning Project of Guangdong Province (2019A030317020)
- National Natural Science Foundation of China (81802257, 81871859, 81772457, 82172750, 82172811)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- immune checkpoint inhibitors, immunotherapy, pan-cancer, multi-omics integration, prognostic factors, immune cell infiltration, mutational landscape, immunogenicity, pathway enrichment, survival analysis, web server, cancer genomics
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Immunotherapy, Mutation, Neoplasms, Biomarkers, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.